Implementation of surgeon-initiated Oncotype DX ordering among patients with breast cancer to reduce chemotherapy wait times.

被引：0
|
作者：
Losk, Katya
Freedman, Rachel A.
Lin, Nancy U.
Golshan, Mehra
Lester, Susan
Pochebit, Stephen
Natsuhara, Kelsey
Camuso, Kristen
King, Tari A.
Bunnell, Craig A.
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Brigham & Womens Faulkner Hosp, Boston, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 08期
关键词：
D O I：
10.1200/JCO.2017.35.8_suppl.166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer
    Rajakumar, L.
    Glendenning, J.
    Hall, J.
    Burcombe, R.
    McCormick, G.
    Hegarty, G.
    Harper-Wynne, C.
    Brown, B.
    Moss, C.
    Thomas, C.
    Jyothirmayi, R.
    Osman, M.
    Nikiforidis, L.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E111 - E111
  • [32] The impact of adjuvant chemotherapy on overall survival in hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis
    Kumar, Prashanth Ashok
    Wang, Dongliang
    Huang, Danning
    Sivapiragasam, Abirami
    CANCER RESEARCH, 2023, 83 (05)
  • [33] Utilization and survival benefit of radiation therapy among hormone receptor positive breast cancer patients with recurrence score from Oncotype DX testing
    Zhang, L.
    Hsieh, M-C
    Petkov, V. I.
    Wu, X-C
    Yu, Q.
    CANCER RESEARCH, 2019, 79 (04)
  • [34] Does Clinicopathologic Features Influence the Use of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients Who Have an Oncotype DX Intermediate Risk Score?
    Nguyen, M. T.
    Chen, Z.
    D'Alfonso, T.
    Stessin, A.
    Nagar, H.
    Hayes, M.
    Shin, S. J.
    MODERN PATHOLOGY, 2013, 26 : 59A - 59A
  • [35] Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
    Katz, D.
    Feldhamer, I.
    Hammerman, A.
    Goldvaser, H.
    Goldstein, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S284 - S284
  • [36] Does Clinicopathologic Features Influence the Use of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients Who Have an Oncotype DX Intermediate Risk Score?
    Nguyen, M. T.
    Chen, Z.
    D'Alfonso, T.
    Stessin, A.
    Nagar, H.
    Hayes, M.
    Shin, S. J.
    LABORATORY INVESTIGATION, 2013, 93 : 59A - 59A
  • [37] Oncotype-DX recurrence score distribution among breast cancer patients harboring a germline mutation in the BRCA1/2 genes.
    Lewin, Ron
    Rizel, Shulamith
    Hendler, Daniel
    Neiman, Victoria
    Ben-Aharon, Irit
    Liebermann, Nicky
    Margel, David
    Zoref, Dalia
    Sulkes, Aaron
    Yerushalmi, Rinat
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31
    Berger, Natalie F.
    Zimmerman, Brittney S.
    Tharakan, Serena
    Suchman, Kelly
    Cascetta, Krystal P.
    Blanter, Julia
    Moshier, Erin
    Ru, Meng
    Jaffer, Shabnam
    Tiersten, Amy
    ONCOLOGY, 2021, 99 (11) : 699 - 702
  • [39] 21-Gene Recurrence Score Index (ONCOTYPE DX) as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer
    Cudos, Ariadna Gasol
    Murillo, Serafin Morales
    Der-Abrain, Noemi Tuset
    Villellas, Felip Vilardell
    Cid, Laura Arbones
    Olive, Jordi Mele
    Morales, Carles Canosa
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004–2015
    Lu Zhang
    Mei-Chin Hsieh
    Valentina Petkov
    Qingzhao Yu
    Yu-wen Chiu
    Xiao-Cheng Wu
    Breast Cancer Research and Treatment, 2020, 180 : 491 - 501
12345